AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

Por Zielinski, Christoph C, Pinto, Carmine
Publicado no ESMO Open (2016)

ESMO Open—Cancer Horizons and the future of oncology

Por Zielinski, Christoph C
Publicado no ESMO Open (2016)

CSCO joins ESMO Open—Cancer Horizons

Por Zielinski, Christoph C, Wu, Yi-Long
Publicado no ESMO Open (2016)

ESMO Open: news in breast cancer 2019

Por Lambertini, Matteo
Publicado no ESMO Open (2020)

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

Por Ohe, Yuichiro, Zielinski, Christoph
Publicado no ESMO Open (2017)

ESMO Open special series on new emerging targets in cancer immunotherapy

Por Lambertini, Matteo
Publicado no ESMO Open (2020)

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

Por Morgan, Gilberto, Preusser, Matthias, Zielinski, Christoph
Publicado no ESMO Open (2020)

One year of ESMO Open: Cancer Horizons—where are we going from here?

Por Zielinski, Christoph
Publicado no ESMO Open (2017)

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Por Preusser, Matthias
Publicado no ESMO Open (2019)

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

Por Burke, Patrick W, Hoelzer, Dieter, Park, Jae H, Schmiegelow, Kjeld, Douer, Dan
Publicado no ESMO Open (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Por Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Publicado no ESMO Open (2020)

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

Por Awada, Ahmad, Gligorov, Joseph, Jerusalem, Guy, Preusser, Matthias, Singer, Christian, Zielinski, Christoph
Publicado no ESMO Open (2019)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Por Lambertini, Matteo, Preusser, Matthias, Zielinski, Christoph C
Publicado no ESMO Open (2019)

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Por Lamarca, A., Foster, L., Satyadas, T., Siriwardena, A., Valle, J.W.
Publicado no ESMO Open (2021)

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Por Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
Publicado no ESMO Open (2021)

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Por Shi, L., Xu, C., Ma, Y., Ou, Q., Wu, X., Lu, S., Shao, Y., Guo, R., Kong, J.
Publicado no ESMO Open (2021)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue...

Por Lee, R.J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., Aung, T., Banfill, K., Baxter, M., Boyce, H., Brearton, G., Copson, E., Dickens, E., Eastlake, L., Gomes, F., Hague, C., Harrison, M., Horsley, L., Huddar, P., Hudson, Z., Khan, S., Khan, U.T., Maynard, A., McKenzie, H., Palmer, D., Robinson, T., Rowe, M., Thomas, A., Tweedy, J., Sheehan, R., Stockdale, A., Weaver, J., Williams, S., Wilson, C., Zhou, C., Dive, C., Cooksley, T., Palmieri, C., Freitas, A., Armstrong, A.C.
Publicado no ESMO Open (2021)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO...

Por Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.
Publicado no ESMO Open (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

Por De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Caputo, R., Cianniello, D., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Publicado no ESMO Open (2021)

In the literature: April 2017

Por Cervantes, Andrés
Publicado no ESMO Open (2017)